This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Site Enhances New Modality CRDMO Platform Capacity for Customers
Medicfibers in collaboration with AIIMS New Delhi, has developed an antimicrobial solution Viroclog that when applied as a coating on textiles, provides long-lasting protection against HAI by reducing virus, bacteria, fungi survival on fabric
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
It includes both public and private health facilities including hospitals, clinics, diagnostic laboratories, and imaging centers
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Subscribe To Our Newsletter & Stay Updated
